ACLX 002
Alternative Names: ACLX-002; ARCL-002; CD123-targeted therapy-ArcellxLatest Information Update: 27 May 2024
At a glance
- Originator Arcellx
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 31 Dec 2023 Arcellx has patent pending for ddBC and SparX technology in the US, Europe, Australia, Eurasia, Israeli, Indonesia, India, Japan, Mexico, Singapore, South Africa, Hong Kong, Monaco, Philippines, New Zealand, South Korea
- 31 Dec 2023 Arcellx has patent protection for ddBC and SparX technology in the US, Europe, Australia, Eurasia, Israeli, Indonesia, India, Japan, Mexico, Singapore, South Africa, Hong Kong, Monaco, Philippines, New Zealand, South Korea
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio